Moleculin Biotech, Inc.
MBRX
$2.34
-$0.10-4.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 336.21% | -244.33% | -76.89% | -29.50% | 35.88% |
| Total Depreciation and Amortization | -70.97% | -31.25% | -9.68% | -3.13% | -11.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5,478.77% | 741.98% | 290.27% | 232.90% | -80.03% |
| Change in Net Operating Assets | 79.64% | -421.02% | 19.86% | 176.32% | -67.45% |
| Cash from Operations | -5.57% | -18.16% | 6.17% | 32.05% | -3.80% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 749,400.00% | 36.80% | -- | -- | -99.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 748,600.00% | 36.83% | 21,792.00% | -- | -99.97% |
| Foreign Exchange rate Adjustments | 220.00% | -142.86% | -100.00% | 133.33% | -650.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.42% | 40.69% | 97.34% | 151.12% | -398.25% |